A Phase 2 interventional study of KADCYLA 160 MG Injection in Metastatic HER2-positive Breast Cancer With Brain Metastasis, sponsored by Jules Bordet Institute. Withdrawn. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-29.
Sponsored by Jules Bordet Institute · Phase 2, Interventional, and Treatment
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms — 11 open to participants now, 16 under way, 2 of them phase 3. Ado-Trastuzumab Emtansine · Breast Neoplasms.
Among the 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms, this one is the 54th largest by enrollment, is one of 2 that started in 2018, is one of 26 in phase 2, and was the 39th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →11 of the 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:
University of Chicago · Sites in Nigeria
Ages 18+ · Women only
UNICANCER · Sites in France
Ages 18+
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–70 · Women only
University of Virginia · Sites in United States
Ages 18+
By country, each count listing its studies:
Ado-Trastuzumab Emtansine: first FDA approval 2013 (KADCYLA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, Ado-Trastuzumab Emtansine is the treatment under test here. Read study by study →
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 32 · Phase 3 12 · Phase 4 1
First in 2006; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 103 across the 56 interventional studies. Of the 36 that completed or were terminated, 24 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 56 have an industry lead sponsor. The 10 most frequent:
Jules Bordet Institute is the lead sponsor of 106 studies on the registry; 27 are open to participants now.
42 studies in Breast Neoplasms by Jules Bordet Institute: 7 open now, 9 under way, none of them phase 3. Of 23 finished, 2 (9%) have results posted.
Among the 42 studies in Breast Neoplasms by Jules Bordet Institute, this one is the 34th largest by enrollment of the 38 interventional ones that give a count, is one of 2 that started in 2018, is one of 25 in phase 2, and was the 28th registered.
Jules Bordet Institute’s Breast Neoplasms studies by the year they started, since 2003.
3 of the studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06481956Zheng YabingT-DM1 Combined With CDK4/6 Inhibitor Ribociclib | 2027-01-10 |
| NCT04733118MedSIRChemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer | 2027-03 |
| NCT07825753Fudan UniversityProtein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms, from their registry updates:
Among Jules Bordet Institute’s 42 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
Women with breast cancer often develop metastases in the brain. Currently, treatment of these metastases is difficult and relies on radiotherapy or surgery which often fail. Therefore, development of new methods of treatment for breast cancer with brain metastasis is very important. T-DM1 is a drug that is already in everyday use for a specific type of breast cancer called HER2-positive breast cancer. The objective of this study is to investigate whether T-DM1 is also effective in brain metastasis and can help patients to live longer and better
This is a multicentre, non-randomised, open label, single arm, phase II study of T-DM1 in patients with metastatic breast cancer and with brain metastasis who have already failed at least one line of anti-HER2 therapy for systemic disease. The study sample is composed of 2 distinct cohorts of patients.
Cohort number 1 is composed of patients with asymptomatic or oligosymptomatic brain metastasis (single or multiple), measurable according to RECIST 1.1, who have not received any local therapy (neither surgery, radiosurgery nor whole brain radiotherapy) for brain metastasis.
Cohort number 2 is composed of patients with brain metastasis (single or multiple), measurable according to RECIST 1.1, previously treated with local therapy (surgery, radiosurgery or whole brain radiotherapy) and with radiologically confirmed brain progression, with a minimum period of 3 months between the end of local therapy and brain progression.
A total number of 110 are planned for screening, in order to enrol 97 patients. A minimum of 87 evaluable patients is necessary. Inclusion of patients in both cohorts will follow a two-stage Simon optimal design. During the study, both brain assessments via magnetic-resonance imaging (MRI) and systemic assessments with computerised tomography (CT) will be performed every 3 cycles (9 weeks) of therapy.
Study treatment consists of T-DM1, 3.6 mg/kg every 3 weeks. Patients will receive study medication until unacceptable toxicity, voluntary withdrawal from study treatment, disease progression, death or pregnancy, whichever occurs first. Patients who experience only progression in the brain and who receive local therapy may remain in the study until systemic progression (or any of the other reasons stated previously), at the investigator's discretion.
After the end of study treatment, all patients will have a safety visit within 30 days (+/- 7 days) from the last T-DM1 administration date. After the safety visit, according the reason of end of study treatment, the follow-up period will begin, as described below:
During efficacy follow-up, 9 weekly efficacy assessments continue according to the same timetable they would have followed had treatment interruption not occurred. This consists of imaging assessments (MRI and CT) and medical visits, as well as QoL evaluations. During this period, treatment is at the discretion of the local physician/investigator.
This follow-up is to continue until disease progression or until voluntary withdrawal of the patient from the study. In case this follow-up is impossible (due to patient refusing to perform assessments or other reasons), survival data can be collected every 6 months via chart review or telephone. Patients in follow-up who are of childbearing potential must be tested for pregnancy at 3 months and at 7 months after end of study treatment. Once a patient has progressed while on efficacy follow-up, they will enter into survival follow-up as per description above.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must meet all these criteria in order to be eligible for the study:
General Criteria:
Adequate organ function, evidenced by the following laboratory results. Exams are to be performed at a maximum of 7 days before enrolment.
Cohort 1 additional specific criteria:
Cohort 2 additional specific criteria:
Exclusion Criteria:
Patients who exhibit any of the following conditions at screening will be ineligible for admission into the study:
General Criteria:
Cohort 1 : additional specific criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
trastuzumab emtansine given every 3 weeks at the standard dose (3.6 mg/kg) via intravenous infusion, until disease progression, intolerable toxicity or consent withdrawal. A median of 9 cycles per patient is expected
Drug: KADCYLA 160 MG Injection
Kadcyla 160Mg Powder for Injection: 3.6 mg/kg iv every 3 weeks
Also known as: T-DM1, trastuzumab emtansine
Clinical Benefit (CB)
defined as complete response plus partial response plus stable disease in the brain, measured by RECIST 1.1, as determined by the local investigators.
Time frame: 9 weeks
CB in the brain RECIST 1.1
measured by RECIST 1.1 criteria, as determined by central evaluation
Time frame: 9 weeks
CB in the brain RANO
measured by RANO brain metastases criteria, as determined by the local investigators
Time frame: 9 weeks
General and cardiac-specific safety
AEs and SAEs according NCI-CTCAE v4.03
Time frame: up to 30 days after last treatment administration
CB: Systemic
defined as complete response plus partial response plus stable disease in non brain areas
Time frame: 9 weeks
CB: bi-compartmental
defined as complete response plus partial response plus stable disease in the whole body
Time frame: 9 weeks
Overall Response (OR) in the brain
defined as complete response plus partial response in brain
Time frame: 9 weeks
Overall Response (OR) systemic
defined as complete response plus partial response in non brain
Time frame: 9 weeks
Overall Response (OR) bi-compartmental
defined as complete response plus partial response in the whole body
Time frame: 9 weeks
Best Response (BR) in the brain
defined as the best obtained response in the brain
Time frame: 1 year
Best Response (BR) systemic
defined as the best obtained response in the non brain
Time frame: 1 year
Best Response (BR) bi-compartmental
defined as the best obtained response in the whole body
Time frame: 1 year
Brain Progression free survival (PFS)
defined as time between enrolment in the study and progression in the brain
Time frame: 1 year
Systemic PFS
defined as time between enrolment in the study and progression in areas other than the brain
Time frame: 1 year
Bi-compartmental PFS
defined as time between enrolment in the study and progression of disease
Time frame: 1 year
Duration of response in the brain
defined as time from documentation of tumour response in the brain (PR or CR) to disease progression in the brain
Time frame: 1 year
Duration of response systemic
systemic defined as time from documentation of non-brain tumour response (PR or CR) to non-brain progression
Time frame: 1 year
Duration of response bi-compartmental
Bi-compartmental defined as time between response and progression
Time frame: 1 year
Duration of Clinical Benefit (DCB) in the brain
defined as the time elapsed between determination of SD, PR or CR and determination of disease progression in the brain
Time frame: 1 year
Duration of Clinical Benefit (DCB) systemic
defined as the time elapsed between determination of SD, PR or CR and determination of systemic disease progression
Time frame: 1 year
Duration of Clinical Benefit (DCB) bi-compartmental
defined as the time elapsed between determination of SD, PR or CR and determination of bi-compartmental disease progression
Time frame: 1 year
Overall survival
defined as time between enrolment in the study and death
Time frame: 1 year
Quality of life
Quality of life will be assessed using the EORTC validated questionnaires
Time frame: 1 year
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2018 to primary completion in Aug 2018, 6 months.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ado-Trastuzumab Emtansine